<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02951494</url>
  </required_header>
  <id_info>
    <org_study_id>AlterG-Training-I Studie</org_study_id>
    <nct_id>NCT02951494</nct_id>
  </id_info>
  <brief_title>Impact of Lower Body Weight Support Using an AlterG Anti-Gravity Treadmill on Cardiopulmonary Exercise Capacity and Trainability</brief_title>
  <official_title>Einfluss Der Körpergewichtsunterstützung Auf Einem AlterG®-Antigravitationslaufband Auf Die Kardiopulmonale Leistungsfähigkeit Und Trainierbarkeit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medicine Greifswald</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medicine Greifswald</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AlterG®-anti-gravity treadmill provides lower body weight support which enables
      individuals to exercise without feeling their full body weight. How this body weight support
      influences cardiovascular, respiratory, vascular and metabolic parameters is currently
      unclear. Further, whether body weight support influences the trainability in response to
      moderate continuous exercise is unknown. This investigation has two main goals. First, we
      explore the direct influence of lower body weight support on cardiometabolic parameters
      during maximal exercise testing. Second, we aim to compare changes in cardiorespiratory
      fitness in response to a structured exercise protocol using moderate intensity with and
      without lower body weight support.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximal oxygen consumption</measure>
    <time_frame>12 weeks</time_frame>
    <description>VO2peak [ml/min]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oxygen consumption at anaerobic threshold</measure>
    <time_frame>12 weeks</time_frame>
    <description>VO2@AT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AlterG Anti-gravity treadmill</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>cont. aerobic exercise training with lower body weight support</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise without body weight support</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>cont. aerobic exercise training without lower body weight support</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>AlterG Anti-gravity treadmill</intervention_name>
    <description>Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill</description>
    <arm_group_label>AlterG Anti-gravity treadmill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  maximal oxygen consumption below age-sex specific standard

        Exclusion Criteria:

          -  acute infection within the last four weeks

          -  anemia (males: Hb &lt; 8.1 mmol/L; females Hb &lt; 7.4 mmol/L)

          -  previous reports of myo-, endo, or pericarditis

          -  previous stroke or acute myocardial infarction

          -  heart failure (NYHA &gt; 1)

          -  aortic valve stenosis

          -  congenital heart disease

          -  cardiomyopathy

          -  severe left ventricular hypertrophy

          -  cardiac arrythmias

          -  hypertension

          -  diabetes

          -  BMI &gt; 35

          -  cancer

          -  pregnancy

          -  aneurysm of aorta or cerebral arteries
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marcus Dörr, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medicine Greifswald</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcus Dörr, M.D.</last_name>
    <phone>+49 38384 8680500</phone>
    <email>mdoerr@uni-greifswald.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Bahls, Ph.D.</last_name>
    <phone>+49 38384 8680500</phone>
    <email>martin.bahls@uni-greifswald.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular examination center of the University Medicine Greifswald</name>
      <address>
        <city>Greifswald</city>
        <zip>17489</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Bahls, Ph.D.</last_name>
      <phone>+49 3834 8680500</phone>
      <email>martin.bahls@uni-greifswald.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2016</study_first_submitted>
  <study_first_submitted_qc>October 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2016</study_first_posted>
  <last_update_submitted>October 28, 2016</last_update_submitted>
  <last_update_submitted_qc>October 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

